ICOS and neoplasm: It has been demonstrated that the efficacy of Ipilimumab (anti CTLA4) was partly due the recruitment of ICOS+ T cells into the tumor; and that in mice lacking ICOS, anti-CTLA4 therapy was much less effective14.